Breast Cancer Liquid Biopsy Market Size, Share, Growth Report 2030

The global breast cancer liquid biopsy market is predicted to grow to USD 357.05 million by 2028, up from USD 87.64 million in 2021. The global breast cancer liquid biopsy market is expected to grow at a CAGR of 19.9 percent over the forecast period. This report discusses market research on the breast cancer liquid biopsy market, its market growth factors, and its challenges. The report also talks about the opportunities available to stakeholders, researchers, and potential investors for the breast cancer liquid biopsy market, discussing the recent changes due to the pandemic.

Breast Cancer Liquid Biopsy Market: Overview

A non-invasive blood test for breast cancer detects tumor DNA fragments and circulating tumor cells (CTCs), which are discharged into the blood from primary tumors and metastatic sites. It is the process of detecting tumor cells in a liquid blood sample taken from the malignant site of interest. Breast cancer liquid biopsy is a straightforward and precise alternative to surgical biopsy procedures that allows doctors and surgeons to diagnose and treat breast cancer early and collect tumor information from blood samples. It aids doctors in comprehending the molecular alterations and dynamics of breast cancer. Furthermore, breast cancer recurrence is predicted to be comprehended using well-timed liquid biopsy procedures for breast cancer.

COVID-19 Impact:

COVID-19 has had a negative impact on market growth. COVID-19 diagnosis and treatment were given priority at many healthcare facilities because of the global implementation of lockdown. An early cancer diagnosis has been halted and cancer-related therapies, visits, and operations have all decreased significantly. Supplies of cancer diagnostic raw ingredients and components necessary to manufacture liquid biopsy kits have been hampered due to logistical constraints.

Breast Cancer Liquid Biopsy Market: Growth Drivers

Surge in the global occurrence of breast cancer to drive the global market

The recent upsurge in cases of breast cancer is one of the primary reasons driving the market growth. Breast cancer is the most common type of cancer among women worldwide, as per the WHO. Breast cancer affects over 2.1 million women each year, and it is the leading cause of cancer-related death in women. Breast cancer claimed the lives of an estimated 627,000 women in 2018, accounting for over 15% of all cancer mortality in women worldwide. The high incidence of breast cancer and the growing desire for better minimally invasive therapy are the primary drivers of the global breast cancer liquid biopsy market.

Request Free Sample

Breast Cancer Liquid Biopsy Market: Restraints

Low sensitivity of liquid biopsy procedure for breast cancer to restrain the market growth

Liquid biopsy providers are concerned about the procedure's sensitivity, which could lead to misdiagnosis due to tiny levels of circulating genetic material. Specificity is also a concern, as false-positive results might lead to patients being treated needlessly. Because liquid biopsy results lack the desired specificity and sensitivity, physicians and researchers must rely on tissue biopsies instead. To some extent, this is impeding market revenue growth.

Breast Cancer Liquid Biopsy Market: Opportunities

Preference for noninvasive procedures to provide opportunities for growth of the global market

The general trend is toward increasing their preferences for various types of non-invasive healthcare services, whether treatments or diagnosis, which are the major drivers driving the growth of the breast cancer liquid biopsy market during the forecast period. Furthermore, with the introduction of liquid biopsy, personalized medicine adoption & availability have never been easier, and the growing trend of producing personalized treatments will boost the market's overall growth throughout the forecast period.

Breast Cancer Liquid Biopsy Market: Challenges

Lack of awareness and access to liquid biopsy in developing and underdeveloped countries

Several developing countries especially in the Asia Pacific region lack awareness of breast cancer as well as other diagnostic biopsy techniques. With great difficulty, the government was successful in introducing traditional biopsy methods, and bringing forward new methods such as liquid biopsy is difficult. Secondly, these methods are costlier than traditional methods causing significant challenges in the global breast cancer liquid biopsy market.

Breast Cancer Liquid Biopsy Market: Segmentation Analysis

The global market is segmented based on product, application, end-user, and region. By product, the market is segregated into assay kits, instruments, and services. Among these, assay kits are now the leading revenue contributor by product and are expected to expand significantly during the forecast period. The introduction of novel liquid biopsy reagents that perform circulating biomarker analysis and target enrichment, as well as an increase in the count of breast cancer liquid biopsy test procedures, rise in reagent kits’ demand, rise in approval of breast cancer liquid biopsy reagent kits, and advent of novel liquid biopsy reagents that perform circulating biomarker analysis & target enrichment are the major drivers that boost the segment's growth.

By application, the market is divided into cancer diseases, non-cancer disease, and others. Due to technological developments in liquid biopsy systems and increased patient knowledge of safe and non-invasive liquid biopsy testing processes, the diagnostics segment for cancer is the largest stakeholder in the global breast cancer liquid biopsy market, depending on the application.

By end-user, the market is bifurcated into hospitals, laboratories, research centers, and others. Laboratories top the market in the end-user segment since even hospitals tend to send test samples and patients to laboratories for testing and treatment. The increase in collaborations between hospitals and test centers attribute to this.

Report Scope:

Recent Developments

• In 2020, Personalis, Inc. released the NeXT Liquid Biopsy, which uses blood samples from advanced-stage solid tumor cancer patients.
• In 2021, Elio Plasma Complete was launched by Personal Genome Diagnostics Inc. The kit is suitable for examining genetic fingerprints & gene mutations in a variety of cancer types.

Breast Cancer Liquid Biopsy Market: Regional Landscape

Asia Pacific to hold a large market share for the forecast period

Due to an increase in the number of government initiatives to modernize healthcare infrastructure and the rising prevalence of cancer, the breast cancer liquid biopsy market in Asia Pacific is predicted to grow at the fastest CAGR over the forecast period. The growing demand for minimally invasive surgeries in the region is fueling market expansion by reducing hospital stays and total medical costs. North American region is also known to follow pursuit, due to increasing cases of breast cancer and preference for non-intrusive cancer treatments.

Breast Cancer Liquid Biopsy Market: Competitive Landscape

Some of the prominent institutes, medical centers, companies, and diagnostic centers that are key players in the global breast cancer liquid biopsy market and include Myriad Genetics Inc., Sysmex Corporation, Fluxion Biosciences Inc., Biocept Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Biodesix Inc., and Isogen Life Science B.V.

The global breast cancer liquid biopsy market is segmented as follows:

By Product

• Assay Kits
• Instruments
• Services

By Application

• Cancer Diseases
• Non-Cancer Diseases
• Others

By End-User

• Hospitals
• Laboratories
• Research Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa